ChromaDex Corporation (CDXC)

NASDAQ: CDXC · IEX Real-Time Price · USD
3.480
-0.190 (-5.18%)
At close: Mar 28, 2024, 4:00 PM
3.540
+0.060 (1.72%)
After-hours: Mar 28, 2024, 4:59 PM EDT

Company Description

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products.

The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.

It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function.

In addition, it offers phytochemical reference standards, and other research and development services.

The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.

ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

ChromaDex Corporation
ChromaDex logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 106
CEO Robert N. Fried

Contact Details

Address:
10900 Wilshire Blvd, Suite 600
Los Angeles, California 90024
United States
Phone 310-388-6706
Website chromadex.com

Stock Details

Ticker Symbol CDXC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001386570
CUSIP Number 171077407
ISIN Number US1710774076
Employer ID 26-2940963
SIC Code 2833

Key Executives

Name Position
Frank Louis Jaksch Jr. Co-Founder and Chairman
Robert N. Fried Chief Executive Officer and Director
Brianna Gerber Chief Financial Officer
Dr. Andrew Shao Ph.D. Senior Vice President of Global Regulatory and Scientific Affairs
Heather Van Blarcom Senior Vice President of Legal and Corporate Secretary
Alex Worsham Vice President of Global Marketing and Communications
David Kroes Senior Vice President of People Matters
Chu Yan Managing Director of Asia Pacific
Jason Campbell Senior Vice President of Business Development
Kendall Knysch Head of Media Relations and Partnerships

Latest SEC Filings

Date Type Title
Mar 6, 2024 8-K Current Report
Mar 6, 2024 10-K Annual Report
Dec 13, 2023 8-K Current Report
Nov 8, 2023 8-K Current Report
Nov 8, 2023 10-Q Quarterly Report
Sep 7, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 9, 2023 8-K Current Report
Aug 9, 2023 10-Q Quarterly Report
Jul 6, 2023 424B5 Filing
Jul 5, 2023 EFFECT Notice of Effectiveness